Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has appointed Jay Ramsinghani as Vice President of Commercial Strategy and Operations, as announced on May 27, 2020. With over 18 years of experience in the biopharmaceutical sector, particularly in dermatology, Ramsinghani will lead Arcutis' commercial operations as the company moves towards potential product commercialization. Previously, he held senior roles at Alastin and Kythera Biopharmaceuticals. Arcutis is focused on developing innovative treatments for immune-mediated dermatological diseases, with several novel compounds in the pipeline.
Arcutis Biotherapeutics reported a strong financial position with $249.3 million in cash as of March 31, 2020, up from $101.3 million at year-end 2019, sufficient to fund operations through 2021. Despite COVID-19 challenges, the company anticipates no delays in clinical timelines and expects six data readouts over the next 18 months. Significant advancements include two Phase 3 trials of roflumilast cream for plaque psoriasis, with topline data expected in 2021. The net loss for Q1 2020 stood at $28 million, compared to $6.7 million in Q1 2019.